Myriad Genetics (MYGN) Competitors

Dynavax Technologies (NASDAQ:DVAX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Does the media prefer DVAX or MYGN?

In the previous week, Myriad Genetics had 10 more articles in the media than Dynavax Technologies. MarketBeat recorded 18 mentions for Myriad Genetics and 8 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 0.97 beat Myriad Genetics' score of 0.22 indicating that Dynavax Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dynavax Technologies	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	4 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has stronger valuation & earnings, DVAX or MYGN?

Dynavax Technologies has higher earnings, but lower revenue than Myriad Genetics. Dynavax Technologies is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynavax Technologies	$294.62M	4.51	$27.31M	-$0.52	-21.27
Myriad Genetics	$832.90M	0.68	-$127.30M	-$4.28	-1.43

Do analysts rate DVAX or MYGN?

Dynavax Technologies presently has a consensus target price of $24.00, suggesting a potential upside of 117.00%. Myriad Genetics has a consensus target price of $12.45, suggesting a potential upside of 104.17%. Given Dynavax Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Dynavax Technologies is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynavax Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Myriad Genetics	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Do insiders & institutionals hold more shares of DVAX or MYGN?

97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by company insiders. Comparatively, 2.4% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is DVAX or MYGN more profitable?

Dynavax Technologies has a net margin of -20.39% compared to Myriad Genetics' net margin of -47.45%. Dynavax Technologies' return on equity of 3.59% beat Myriad Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynavax Technologies	-20.39%	3.59%	2.20%
Myriad Genetics	-47.45%	-5.17%	-3.44%

Which has more volatility & risk, DVAX or MYGN?

Dynavax Technologies has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Summary

Dynavax Technologies beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.